September 22, 2010

Gilenya approved for multiple sclerosis

GILENYA (fingolimod) 0.5mg capsules by Novartis
GILENYA (fingolimod) 0.5mg capsules by Novartis
The FDA has approved Gilenya (fingolimod capsules, from Novartis), a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. This approval was based on study data which demonstrated that Gilenya reduced relapses by 52% (p<0.001) at one year compared with interferon beta-1a IM (Avonex, from Biogen Idec). Gilenya also reduced disease activity as measured by the number of new and newly enlarged T2 lesions on MRI scans compared to interferon beta-1a IM (1.6 vs 2.6, respectively, p=0.002) at one year.

Data from a two-year placebo-controlled study showed a reduction in relapse rate (54% reduction, p<0.001) and risk of disability progression among Gilenya patients (30% reduction confirmed at 3-month follow-up visit, p=0.02). In both studies, treatment with Gilenya also resulted in statistically significant reductions in brain lesion activity as measured by MRI.

Gilenya will be available in early October in a 0.5mg dosage strength.

For more information call (877) 408-4974 or visit www.gilenya.com.
This article originally appeared on MPR.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs